On November 14th, 2025, World Diabetes Day, #insulin4all advocates across the globe came together to make a demand: that they be able to access and afford their life-sustaining medications. Recent data showed that 1 in 3 people around the world rationed their insulin due to cost in 2024. At T1International, we know that #insulin4all is a reasonable and dignified demand– and yet, we are still too far from achieving a reality where everyone, no matter where they live, has access to the medicine and supplies they need to survive and flourish. Read more
On Thursday, September 25, 2025, T1International brought policy leaders, advocates, and patients together at NYU Law for “Fixing a Broken System: The Path to Public Pharma in New York,” a major public event highlighting the urgent need for publicly controlled pharmaceutical production to counter skyrocketing drug prices. Read more
On World Diabetes Day, we shine a spotlight on a glaring injustice: millions of people with diabetes in low- and middle-income countries are denied access to affordable insulin pens—a delivery method that could save and transform lives. Pharmaceutical giants Eli Lilly, Novo Nordisk, and Sanofi have monopolized the diabetes market, prioritizing profit over people. It’s time to demand change. It’s time to make it right. Read more
On March 16, 2024, hundreds of #insulin4all advocates participated in over a dozen events across the globe calling for insulin access and affordability as part of the Global Day of Action for #insulin4all, sharing their stories on the critical need for insulin equity now. Read more
As I listened to the amazing sessions at this year's Summit, the rage from 2016 was still there, and rightly so, but there was also so much love, inclusivity and power. Whether you like the term 'patients' or not - we debated it at the Summit - this event was full of patients taking back their power. I was proud to be part of it and continue to be proud that T1International is making such a huge global impact as a small, pharma-free charity. Read more